The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.
作者信息
Schafer Jason J, Ravi Saranyu, Rowland Evelyn V, Shenoda Germin, Leon Nicholas
出版信息
P T. 2011 Jun;36(6):346-64.
Abstract
摘要
相似文献
1
2
HIV-1 Antiretroviral Resistance in Cuba, 2009-2014.古巴 2009-2014 年 HIV-1 抗逆转录病毒耐药性
MEDICC Rev. 2018 Jul;20(3):15-21. doi: 10.37757/MR2018.V20.N3.5.
3
Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.对非核苷类逆转录酶抑制剂耐药的人类免疫缺陷病毒突变体的结构和生化效应
Int J Biochem Cell Biol. 2004 Sep;36(9):1735-51. doi: 10.1016/j.biocel.2004.02.026.
4
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.三种高效抗逆转录病毒治疗策略的比较：在核苷类逆转录酶抑制剂存在的情况下，分别使用非核苷类逆转录酶抑制剂、蛋白酶抑制剂或两者联合作为初始治疗（CPCRA 058 FIRST研究）：一项长期随机试验。
Lancet. 2006 Dec 16;368(9553):2125-35. doi: 10.1016/S0140-6736(06)69861-9.
5
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.用于治疗HIV感染患者的抗逆转录病毒药物的药代动力学及潜在相互作用。
Clin Pharmacokinet. 1999 Apr;36(4):289-304. doi: 10.2165/00003088-199936040-00004.
6
HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.人类免疫缺陷病毒1型对第一代和第二代非核苷类逆转录酶抑制剂的耐药性。
AIDS Rev. 2009 Jul-Sep;11(3):165-73.
7
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.依非韦伦或奈韦拉平与两种核苷类或核苷酸类逆转录酶抑制剂联合用于初治抗逆转录病毒治疗的HIV感染者的初始治疗。
Cochrane Database Syst Rev. 2016 Dec 10;12(12):CD004246. doi: 10.1002/14651858.CD004246.pub4.
8
Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms.非核苷类逆转录酶抑制剂与核苷类逆转录酶抑制剂突变之间的相互作用：表型与机制
Curr Opin HIV AIDS. 2007 Mar;2(2):88-93. doi: 10.1097/COH.0b013e328055505c.
9
Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection.三联核苷类似物抗逆转录病毒疗法：拓展人类免疫缺陷病毒感染管理的治疗方法
Expert Opin Investig Drugs. 1999 Aug;8(8):1147-55. doi: 10.1517/13543784.8.8.1147.
10
Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).双（杂芳基）哌嗪类化合物（BHAPs）作为非核苷类逆转录酶抑制剂（NNRTIs）抗人类免疫缺陷病毒 1 型（HIV-1）的研究进展。
Mini Rev Med Chem. 2010 Jan;10(1):62-72. doi: 10.2174/138955710791112578.
本文引用的文献
1
Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.依曲韦林在感染HIV-1的孕妇中的安全性和药代动力学。
HIV Med. 2011 Apr;12(4):257-8. doi: 10.1111/j.1468-1293.2010.00874.x.
2
Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.依曲韦林与非抗逆转录病毒药物的药代动力学相互作用。
Clin Pharmacokinet. 2011 Jan;50(1):25-39. doi: 10.2165/11534740-000000000-00000.
3
Antiretroviral treatment for children with peripartum nevirapine exposure.围产期接触奈韦拉平的儿童的抗逆转录病毒治疗。
N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.
4
Antiretroviral therapies in women after single-dose nevirapine exposure.女性单次奈韦拉平暴露后的抗逆转录病毒治疗。
N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.
5
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.治疗药物监测与药物基因检测相结合以优化依非韦伦治疗。
Ther Drug Monit. 2010 Oct;32(5):579-85. doi: 10.1097/FTD.0b013e3181f0634c.
6
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.血液透析对需要血液透析的HIV-1感染者中奈韦拉平的药代动力学无显著影响：ACTG A5177研究结果
J Acquir Immune Defic Syndr. 2010 Aug;54(4):e7-9. doi: 10.1097/QAI.0b013e3181e2d5e5.
7
Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.定量评估美国生育年龄的 HIV 感染女性使用依非韦伦的风险和获益。
HIV Med. 2011 Feb;12(2):97-108. doi: 10.1111/j.1468-1293.2010.00856.x.
8
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.肝损伤对每日两次给予 200 毫克依曲韦林稳态药代动力学的影响：一项在成人中进行的开放标签、多剂量、对照的 I 期研究。
Clin Ther. 2010 Feb;32(2):328-37. doi: 10.1016/j.clinthera.2010.02.013.
9
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.低频非核苷类逆转录酶抑制剂耐药变异体导致接受含依非韦伦方案治疗的经验丰富患者治疗失败。
J Infect Dis. 2010 Mar;201(5):672-80. doi: 10.1086/650542.
10
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.氟康唑联合用药会增加乌干达 HIV 感染者中奈韦拉平的浓度。
J Antimicrob Chemother. 2010 Feb;65(2):316-9. doi: 10.1093/jac/dkp451. Epub 2009 Dec 23.
Zotero 插件